Clinical Trial Update: An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001 [Phase 1]

View source ↗

Summary

An expanded access study of Abiraterone Acetate for advanced prostate cancer has completed after COU-AA-001.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostate Neoplasms | Phase 1 | Status: COMPLETED